Why a Generic Peptide Is Harder Than a Generic Pill: Inside FDA’s July 2026 Guidance Revision

Condor Research supplies characterised reference materials for laboratory research use only. This article is about pharmaceutical quality science and its regulatory framework. Nothing here is a therapeutic claim or a recommendation to use any compound in humans.

The thing that makes peptides different from small molecules

For a conventional small-molecule generic, sameness is close to a solved problem. Aspirin is aspirin. The molecule has one structure, a manageable number of possible impurities, and analytical methods that resolve them cleanly. If you show the same active ingredient at the same strength with an acceptable impurity profile and equivalent absorption, you have a generic.

A peptide breaks that logic in three ways.

It is made by a process that generates near-copies of itself. Solid-phase synthesis builds a chain one residue at a time, and every coupling step is a chance to fail. FDA’s own evaluation of BPC-157 sets out the taxonomy: incomplete coupling reactions, truncations and side reactions produce peptide-related impurities that are, in the agency’s words, “typically similar in structure to the target peptide” and “may be difficult to identify and quantify without sophisticated analytical methods.” A chain missing one residue out of thirty is chemically almost the same molecule. That is precisely what makes it hard to see and hard to dismiss.

It has structure above the sequence. Peptides fold, associate and aggregate. Two batches with identical primary sequence and identical purity by HPLC can differ in the proportion of monomer to dimer to higher-order aggregate, and that difference is invisible to the assay most people rely on. FDA notes that detecting aggregates may require size exclusion chromatography or field flow fractionation, and that peptides are extremely sensitive to formulation, process and environment — pH, temperature, concentration, excipients, in-process impurities — in ways that can cause aggregation and loss of biological activity.

It can be seen by the immune system. A small molecule is generally too small to provoke an adaptive immune response on its own. A peptide of sufficient size, particularly in aggregated form, can. This is why FDA’s conclusions in July 2026 kept returning to the same phrase: because there was no information on impurities and no information on aggregation, the agency “cannot rule out the potential for immunogenicity associated with these impurities and peptide-related aggregates.”

Sequence, in short, is necessary and nowhere near sufficient.

The five things FDA revised, and what each one means

The agency describes the updated recommendations as covering five areas. Each is a direct response to one of the problems above.

1. Submission of recombinantly, synthetically or semi-synthetically produced peptides as ANDAs. This is the structural question. Several reference peptide medicines are made in living cells by recombinant DNA technology. A generic manufacturer would rather make the same peptide by chemical synthesis, which is cheaper and more controllable. But the two routes produce different impurity families — a synthetic route yields deletion sequences and residual reagents; a biological route yields host-cell proteins and DNA — so “the same peptide by a different route” is a genuinely non-trivial claim. The withdrawn 2021 guidance addressed exactly this scenario, and FDA has said it plans to reissue a revised version.

2. Innate immune response testing. The adaptive immune response is the one that produces anti-drug antibodies. The innate response is faster and less specific, and certain process-related impurities can trigger it independently of the peptide itself. Requiring this testing acknowledges that a product’s immunological behaviour is a property of the whole manufactured article, not just of the active molecule.

3. Impurity thresholds. The rule-setting question: how much of a near-identical impurity is acceptable, and at what level must an impurity be identified and qualified rather than merely reported. For peptides the thresholds cannot simply be inherited from small-molecule practice, because both the number and the biological relevance of the impurities are different.

4. Higher order structure assessment. The explicit demand that applicants characterise conformation and association state, not only composition. This is the regulatory acknowledgement that a peptide is not fully described by its sequence.

5. Biological activity assessment. Demonstrating that the material does what it is supposed to do at the receptor, in an assay. Chromatographic purity says how much of the sample is the target peptide. It does not say whether that peptide is correctly folded, correctly disulfide-bonded, or active. Those are separate measurements, and FDA now wants the separate measurement.

Read together, the five form a coherent statement: a peptide product is defined by identity, purity, impurity profile, higher order structure and potency, and a submission that supplies only some of these has not characterised the product.

What this has to do with research-grade material

Everything, and this is the part worth sitting with.

The five criteria above are what a regulator asks of a company that wants to sell a copy of an approved medicine. Nobody applies that standard to a research reagent, nor should they — a reference material for laboratory work is not a drug and does not need a drug’s dossier.

But the analytical problems are properties of peptide chemistry, not of regulatory status. A deletion sequence does not know whether the vial it is in will be used in a clinical trial or a cell culture. Aggregation happens on the same timescale in both. And a certificate of analysis reporting a single purity figure conveys exactly the same limited information either way — and it is a common reason peptide experiments fail to reproduce.

FDA made that point in July 2026, in a passage that deserves to be read by everyone in this sector. Reviewing available certificates of analysis for BPC-157 — a compound whose purity and identity data we have published on directly — the agency found that most “only contain purity testing results”, with “no information about the impurity limits/testing results … to demonstrate control of the impurity profile.”

That is not an argument about compounding. It is an observation about what the market’s documentation currently contains.

What a genuinely informative certificate of analysis would show

Stated neutrally, as a specification rather than a sales pitch, a peptide COA that answers the questions FDA’s framework asks would report at minimum:

• Identity, by mass spectrometry, confirming the observed mass matches the theoretical mass for the stated sequence. Purity by HPLC alone does not establish identity; it establishes homogeneity.
• Purity, by a stated chromatographic method, with the method, column, gradient and detection wavelength named, and the chromatogram attached rather than summarised.
• Impurity profile, not just a residual percentage. Which peaks, at what relative retention, at what level, and whether any are identified.
• Water and counter-ion content, since peptides are typically supplied as acetate or trifluoroacetate salts and are hygroscopic. Net peptide content can differ substantially from vial weight, which matters for anyone computing a concentration.
• Aggregation state, where the peptide’s size and application make it relevant, by an orthogonal method.
• Batch identity and date, so the certificate refers to the material in hand rather than to a representative batch tested at some point in the past.

None of that turns a reagent into a medicine. It is simply the difference between a document that states a number and a document that lets a researcher evaluate what they have.

The broader point

Peptides occupy an awkward middle ground in pharmaceutical science. They are too large and too structurally rich to be treated like small molecules, and too small and too chemically defined to be treated like biologics. Every regulatory framework applied to them has had to be adapted from one side or the other — the EMA reached the same place from the European direction with its 2026 synthetic peptide guideline — and July 2026 is the latest adaptation — FDA importing analytical expectations from the biologics world into the generic drug pathway.

The most useful thing to take from it is not the regulatory detail. It is the underlying claim, which is true regardless of jurisdiction or product category: for a peptide, purity is one number among several, and on its own it does not describe the material. That was FDA’s finding about the certificates of analysis circulating in this market, and it is the gap the next few years of this industry will be judged on.

Related reading

• How to read a certificate of analysis
• HPLC, mass spectrometry and what a purity figure means
• Net peptide content: the NPC standard
• Endotoxins and sterility on a COA
• The EMA synthetic peptide guideline (2026)
• How to choose a research peptide supplier in Europe

Research peptides and compounds — Europe